Yes, but it will take a bit longer to get a conclusive result because transmission is harder to study.
Data analysis in a study by the Israeli Health Ministry and Pfizer Inc found the Pfizer vaccine developed with Germany’s BioNTech reduces infection, including in asymptomatic cases, by 89.4% and in syptomatic cases by 93.7%. Findings of the pre-published study, not yet peer-reviewed, but based on a national database that is one of the world’s most advanced, were first reported by the Israeli news site Ynet late on Thursday and were obtained by Reuters on Friday. Pfizer declined to comment and the Israeli Health Ministry did not respond to a request for comment. A separate study by Israel’s Sheba Medical Center published on Friday in The Lancet medical journal found that among 7,214 hospital staff who received their first dose in January, there was an 85% reduction in symptomatic COVID-19 within 15 to 28 days with an overall reduction of infections, including asymptomatic cases detected by testing, of 75%. More research is needed to draw a definitive conclusion, but the studies are among the first to suggest a vaccine may stop the spread of the novel coronavirus and not just prevent people getting ill. Michal Linial, a professor of molecular biology and bioinformatics at Jerusalem’s Hebrew University, said the findings were a big step towards answering one of the most important questions in combating the pandemic. “Whether it is 75 or 90 percent reduction doesn’t matter - it is a big drop in transmission,” Linial said. “It means that not only is the individual vaccinated protected, the inoculation also provides protection to his or her surroundings.” The researchers said further study was needed on asymptomatic transmission among people fully vaccinated because they are less likely to be tested for COVID-19. Vaccine developers have also said more research was needed on transmissibility. In December, Germany’s BioNTech said it would take three to six months more study. [0]
---
College students in the United States, vaccinated with Moderna Inc’s COVID-19 vaccine, will be part of a new study to test its effectiveness in curbing the spread of the virus, the COVID-19 Prevention Network said on Friday. The trial, backed by the National Institutes of Health (NIH), is designed to determine if the vaccine, mRNA-1273, can prevent coronavirus infection, limit virus in the nose, and reduce transmission from vaccinated individuals to their close contacts. The Prevent COVID U study, funded by the National Institute of Allergy and Infectious Diseases (NIAID), will monitor about 12,000 young adults across 20 universities over a five-month period. [1]
[0] https://www.reuters.com/article/health-coronavirus-israel-va...
[1] https://www.reuters.com/article/us-health-coronavirus-modern...